2026-04-17T18:47:10Zhttps://recercat.cat/oai/requestoai:recercat.cat:20.500.12327/20782025-10-22T11:12:09Zcom_2072_4428com_2072_4427col_2072_487898
RECERCAT
author
Pleguezuelos, Patricia
author
Sibila, Marina
author
Ramírez, Carla
author
López-Jiménez, Rosa
author
Pérez, Diego
author
Huerta, Eva
author
Llorens, Anna Maria
author
Pérez, Mónica
author
Correa-Fiz, Florencia
author
Mancera Gracia, José Carlos
author
Taylor, Lucas P.
author
Smith, Jennifer
author
Bandrick, Meggan
author
Borowski, Stasia
author
Saunders, Gillian
author
Segalés, Joaquim
author
Lopez-Soria, Sergio
author
Fort, Maria
author
Balasch, Mónica
other
Producció Animal
group
Sanitat Animal
2025-10-22T11:12:09Z
2025-10-22T11:12:09Z
2022-12-09
Pleguezuelos, Patricia, Marina Sibila, Carla Ramírez, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Anna Maria Llorens, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera Gracia, Lucas P. Taylor, Jennifer Smith, Meggan Bandrick, Stasia Borowski, Gillian Saunders, Joaquim Segalés, Sergio López-Soria, Maria Fort and Mónica Balasch. 2022. "Efficacy Studies Against PCV-2 Of A New Trivalent Vaccine Including PCV-2A And PCV-2B Genotypes And Mycoplasma Hyopneumoniae When Administered At 3 Weeks Of Age". Vaccines 10 (12): 2108. doi:10.3390/vaccines10122108.
2076-393X
http://hdl.handle.net/20.500.12327/2078
https://doi.org/10.3390/vaccines10122108
This study aimed to evaluate the efficacy of a new trivalent vaccine containing inactivated
Porcine Circovirus 1-2a and 1-2b chimeras and a Mycoplasma hyopneumoniae bacterin administered to
pigs around 3 weeks of age. This trivalent vaccine has already been proved as efficacious in a splitdose regimen but has not been tested in a single-dose scenario. For this purpose, a total of four studies
including two pre-clinical and two clinical studies were performed. Globally, a significant reduction
in PCV-2 viraemia and faecal excretion was detected in vaccinated pigs compared to non-vaccinated
animals, as well as lower histopathological lymphoid lesion plus PCV-2 immunohistochemistry
scorings, and incidence of PCV-2-subclinical infection. Moreover, in field trial B, a significant increase
in body weight and in average daily weight gain were detected in vaccinated animals compared to
the non-vaccinated ones. Circulation of PCV-2b in field trial A and PCV-2a plus PCV-2d in field trial B
was confirmed by virus sequencing. Hence, the efficacy of this new trivalent vaccine against a natural
PCV-2a, PCV-2b or PCV-2d challenge was demonstrated in terms of reduction of histopathological
lymphoid lesions and PCV-2 detection in tissues, serum and faeces, as well as improvement of
production parameters.
eng
Attribution 4.0 International
Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age
info:eu-repo/semantics/article